What is NDC 59651-582?

59651-582 is the product NDC for Pazopanib, Pazopanib hydrochloride 200 mg/1 tablet, film coated, listed with the FDA by Aurobindo Pharma Limited. It has 3 package NDCs, shown above in 10- and 11-digit form.

Aurobindo Pharma Limited, NDC labeler code 59651. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Pazopanib?

7 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Pazopanib NDC 59651-582 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-582Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0582Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
59651-582-08	5965105820859651058208	120 TABLET, FILM COATED in 1 BOTTLE (59651-582-08)Marketed from Dec 4, 2024
59651-582-30	5965105823059651058230	30 TABLET, FILM COATED in 1 BOTTLE (59651-582-30)Marketed from Dec 4, 2024
59651-582-90	5965105829059651058290	90 TABLET, FILM COATED in 1 BOTTLE (59651-582-90)Marketed from Dec 4, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pazopanib
Generic name (nonproprietary): pazopanib
Active ingredients: Pazopanib hydrochloride — 200 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Aurobindo Pharma LimitedNDC labeler code 59651
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219034
Marketing start: Dec 4, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Protein Kinase Inhibitors (Mechanism)
Identifiers: Product ID 59651-582_25575cc6-5757-4f9b-9c09-0c4deb61ba12SPL ID 25575cc6-5757-4f9b-9c09-0c4deb61ba12SPL set ID 25575cc6-5757-4f9b-9c09-0c4deb61ba12RxCUI 867502UNII 33Y9ANM545UPC 0359651582305
Pharmacologic class: Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651058208 followed by a unit qualifier and the quantity

Package 59651-0582-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 5, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Us…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 59651-582

What is NDC 59651-582?: 59651-582 is the product NDC for Pazopanib, Pazopanib hydrochloride 200 mg/1 tablet, film coated, listed with the FDA by Aurobindo Pharma Limited. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Pazopanib.
What is the active ingredient?: Pazopanib hydrochloride.
Who is the labeler?: Aurobindo Pharma Limited, NDC labeler code 59651. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Pazopanib?: 7 other product NDCs are listed under this name. See all Pazopanib NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Pazopanib NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
pazopanibpazopanib hydrochloride	Pazopanib hydrochloride 400 mg/1	Tablet, Film coatedOral	Torrent Pharmaceuticals Limited	13668-735	13668-0735-3013668-0735-6013668-0735-90
pazopanibpazopanib hydrochloride	Pazopanib hydrochloride 200 mg/1	Tablet, Film coatedOral	Novugen Pharma (USA) LLC.	82293-022	82293-0022-10
Pazopanib	Pazopanib hydrochloride 200 mg/1	Tablet, Film coatedOral	AvKARE	42291-939	42291-0939-12
Pazopanib	Pazopanib hydrochloride 200 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-4184	00480-4184-89
Pazopanib	Pazopanib hydrochloride 200 mg/1	Tablet, Film coatedOral	SUN PHARMACEUTICAL INDUSTRIES, INC.	63304-116	63304-0116-1363304-0116-30
Pazopanib	Pazopanib 200 mg/1	TabletOral	Golden State Medical Supply, Inc.	51407-872	51407-0872-12
Pazopanib	Pazopanib 200 mg/1	TabletOral	Apotex Corp.	60505-4779	60505-4779-0560505-4779-07